Zynex Reports First Quarter 2025 Financial Results

Core Insights - Zynex, Inc. reported a net revenue of $26.6 million for Q1 2025, a decrease from $46.5 million in Q1 2024, primarily due to a temporary suspension of payments from its largest insurance customer, Tricare [4][6] - The company experienced a net loss of $10.4 million, or $0.33 per share, compared to a net income of $10,000 in the same quarter last year [6][18] - Zynex plans to submit its FDA application for the NiCO laser pulse oximeter soon, which is expected to drive new customer acquisition and diversify its product offerings [3] Management Commentary - The company noted a 3% year-over-year decrease in total orders, attributed to a 39% reduction in sales force headcount, but expressed optimism about the productivity of the remaining sales representatives [2] - Zynex is appealing the payment suspension from Tricare and expects a response by June 2025 [2] Financial Performance - Gross profit for Q1 2025 was $18.2 million, representing 69% of revenue, down from 80% in Q1 2024, impacted by the Tricare payment suspension [4] - Sales and marketing expenses decreased by 28% to $16.9 million, while general and administrative expenses rose to $14.4 million from $13.3 million year-over-year [5] Cash Flow and Guidance - Cash flows from operations for Q1 2025 were negative at $10.5 million, with cash and cash equivalents at $23.9 million as of March 31, 2025 [7] - The company anticipates Q2 2025 net revenue of at least $27 million and expects to improve loss per share to ($0.20) or better [8] Balance Sheet Highlights - As of March 31, 2025, Zynex had total assets of $105.8 million, down from $122.1 million at the end of 2024 [15][17] - Current liabilities were $16.3 million, with total liabilities amounting to $85 million [16][17]